Metastatic non-small cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021–2026 - supplementary material

Supplementary Table 1. Available data in country-specific cancer registries.
Supplementary Table 2. Driver mutation literature review.
Supplementary Table 3. Projected incidence of non-squamous (A) and squamous (B) non-small cell lung cancer in five Western European countries 2021–2026.
Supplementary Table 4. Estimated time to progression by line of therapy for non-squamous and squamous non-small cell lung cancer with no known driver mutations.
Supplementary Table 5. Projected number of patients with non-squamous (A) and squamous (B) non-small cell lung cancer with no known driver mutations initiating line of therapy by country and programmed death-ligand 1 status.
Supplementary Table 6. First-line maintenance regimens according to the first-line induction systemic therapy regimen used in Stage IIIB/C and IV non-squamous (A) and squamous (B) non-small cell lung cancer patients with no known driver mutations, Western Europe, 2020.

补充表1. 各国癌症登记处可用数据。
补充表2. 驱动突变（driver mutation）文献综述。
补充表3. 2021-2026年西欧五国非鳞状（A）与鳞状（B）非小细胞肺癌的预计发病率。
补充表4. 无已知驱动突变的非鳞状与鳞状非小细胞肺癌患者按治疗线数划分的预计进展时间。
补充表5. 按国家及程序性死亡配体1（programmed death-ligand 1）状态划分，启动治疗的无已知驱动突变的非鳞状（A）与鳞状（B）非小细胞肺癌患者预计人数。
补充表6. 2020年西欧地区无已知驱动突变的ⅢB/C期及Ⅳ期非鳞状（A）与鳞状（B）非小细胞肺癌患者的一线维持治疗方案，按其所采用的一线诱导系统治疗方案分类。